Annual revenue rose by 30.3 % to 191.791 mln euros, the company said in its 2015 annual report filed with the Center of Registers.
"The sales growth was primarily due to increased sales to the US markets," it said.
Sicor Biotech last year had an average workforce of 219 people, slightly up from 215 in 2014, not including the employees of its Latvian and Estonian units.
Dutch-registered Gatio Investments, which is part of Israel's Teva Pharmaceutical Industries Group, owns 100 % of shares in Sicor Biotech.
